\uff5e \u5927\u624b\u30b0\u30ed\u30fc\u30d0\u30eb\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u304c\u81e8\u5e8a\u8a66\u9a13\u306e\u52b9\u7387\u6539\u5584\u306e\u305f\u3081\u306b<\/p>\n
Vault Study Startup\u3068Vault eTMF\u3092\u63a1\u7528 \uff5e<\/p>\n
2020\u5e748\u670826\u65e5<\/p>\n
Veeva Japan\u682a\u5f0f\u4f1a\u793e<\/p>\n
<\/p>\n Bayer AG\u793e\u306e\u533b\u85ac\u54c1\u7814\u7a76\u958b\u767a\u8cac\u4efb\u8005\u3067\u3042\u308bJoerg Moeller\u6c0f\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300cVeeva\u306e\u30af\u30e9\u30a6\u30c9\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u3067\u3001\u5f53\u793e\u306f\u81e8\u5e8a\u8a66\u9a13\u306e\u5b9f\u65bd\u3092\u30b9\u30ea\u30e0\u5316\u3067\u304d\u308b\u3067\u3057\u3087\u3046\u3002Veeva\u306e\u6700\u5148\u7aef\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u3068\u9867\u5ba2\u4e2d\u5fc3\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u3078\u306e\u53d6\u308a\u7d44\u307f\u3092\u9ad8\u304f\u8a55\u4fa1\u3057\u3066\u3044\u307e\u3059\u3002\u300d<\/p>\n Veeva\u306f\u3001Bayer AG\u793e\u304c\u81e8\u5e8a\u8a66\u9a13\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u3092\u7d71\u5408\u3059\u308b\u305f\u3081\u306b\u3001\u8a66\u9a13\u306e\u30b3\u30f3\u30c6\u30f3\u30c4\u3084\u30c7\u30fc\u30bf\u3092\u5358\u4e00\u306e\u30af\u30e9\u30a6\u30c9\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u4e0a\u3067\u7ba1\u7406\u3067\u304d\u308b\u3088\u3046\u652f\u63f4\u3057\u307e\u3059\u3002Vault Study Startup\u306f\u3001\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u306e\u9078\u629c\u304b\u3089\u627f\u8a8d\u307e\u3067\u306e\u30a8\u30f3\u30c9\u30c4\u30fc\u30a8\u30f3\u30c9\u306e\u81e8\u5e8a\u8a66\u9a13\u30b9\u30bf\u30fc\u30c8\u30a2\u30c3\u30d7\u30d7\u30ed\u30bb\u30b9\u3092\u30b9\u30ea\u30e0\u5316\u3057\u307e\u3059\u3002Vault eTMF\u306f\u3001\u7a4d\u6975\u578b\u2018active\u2019TMF\u7ba1\u7406\u306b\u3088\u3063\u3066\u30ea\u30a2\u30eb\u30bf\u30a4\u30e0\u306e\u53ef\u8996\u6027\u3068\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3092\u5b9f\u73fe\u3057\u3001\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u304c\u30b3\u30f3\u30d7\u30e9\u30a4\u30a2\u30f3\u30b9\u3092\u9075\u5b88\u3057\u306a\u304c\u3089\u5e38\u306b\u67fb\u5bdf\u6e96\u5099\u4f53\u5236\u3092\u7dad\u6301\u3067\u304d\u308b\u3088\u3046\u306b\u3057\u307e\u3059\u3002<\/p>\n \u3053\u306e2\u3064\u306e\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u3092\u7d44\u307f\u5408\u308f\u305b\u308b\u3053\u3068\u3067\u3001Bayer AG\u793e\u306e\u81e8\u5e8a\u8a66\u9a13\u30c1\u30fc\u30e0\u306f\u624b\u4f5c\u696d\u306e\u30d7\u30ed\u30bb\u30b9\u3092\u524a\u6e1b\u3001\u540c\u3058\u8a66\u9a13\u6587\u66f8\u306e\u5171\u6709\u3001\u3055\u3089\u306b\u306fVault Study Startup\u304b\u3089Vault eTMF\u3078\u30b3\u30f3\u30c6\u30f3\u30c4\u3092\u81ea\u52d5\u30d5\u30a1\u30a4\u30ea\u30f3\u30b0\u3067\u304d\u308b\u3088\u3046\u306b\u306a\u308a\u307e\u3059\u3002<\/p>\n Veeva Development Cloud\u30b9\u30c8\u30e9\u30c6\u30b8\u30fc\u62c5\u5f53\u30f4\u30a1\u30a4\u30b9\u30d7\u30ec\u30b8\u30c7\u30f3\u30c8\u3067\u3042\u308bRik Van Mol\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300c\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u3067\u306f\u3001\u5897\u3048\u7d9a\u3051\u308b\u81e8\u5e8a\u8a66\u9a13\u306b\u5bfe\u5fdc\u3059\u308b\u305f\u3081\u3001\u8a66\u9a13\u5b9f\u65bd\u306e\u8fc5\u901f\u5316\u306b\u5411\u3051\u3066Veeva Vault Clinical\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u3092\u63a1\u7528\u3059\u308b\u52d5\u304d\u304c\u5e83\u304c\u3063\u3066\u3044\u307e\u3059\u3002\u4eca\u5f8cBayer AG\u793e\u306f\u3001\u67fb\u5bdf\u6e96\u5099\u4f53\u5236\u3092\u5e38\u306b\u7dad\u6301\u3057\u305f\u72b6\u614b\u3067\u3001\u8a66\u9a13\u306e\u30b9\u30bf\u30fc\u30c8\u30a2\u30c3\u30d7\u304b\u3089\u5b8c\u4e86\u307e\u3067\u306e\u8a66\u9a13\u60c5\u5831\u3092\u5b8c\u5168\u306b\u53ef\u8996\u5316\u3067\u304d\u308b\u3088\u3046\u306b\u306a\u308b\u3067\u3057\u3087\u3046\u3002\u300d<\/p>\n Vault Study Startup\u3068Vault eTMF\u306f\u3001CDMS<\/a><\/strong>\u3001Study Startup<\/a><\/strong>\u3001eTMF<\/a><\/strong>\u3001CTMS<\/a><\/strong>\u3001\u304a\u3088\u3073Payments<\/a><\/strong>\u3092\u542b\u3080\u3001\u81e8\u5e8a\u8a66\u9a13\u306e\u30c7\u30fc\u30bf\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u3068\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u3092\u7d71\u5408\u5316\u3059\u308b\u696d\u754c\u521d\u306e\u30af\u30e9\u30a6\u30c9\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3042\u308bVeeva Vault Clinical Suite<\/a><\/strong>\u306e\u4e00\u90e8\u3067\u3059\u3002Veeva\u306e\u7d71\u5408\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u7fa4\u306f\u81e8\u5e8a\u8a66\u9a13\u696d\u52d9\u5168\u4f53\u3092\u53ef\u8996\u5316\u3057\u3001\u30a8\u30f3\u30c9\u30c4\u30fc\u30a8\u30f3\u30c9\u306e\u81e8\u5e8a\u8a66\u9a13\u30d7\u30ed\u30bb\u30b9\u3092\u30b9\u30ea\u30e0\u5316\u3057\u307e\u3059\u3002<\/p>\n Veeva Vault Clinical Suite\u306b\u3064\u3044\u3066\u306f\u30012020\u5e7410\u670813\uff5e14\u65e5\u306b\u958b\u50ac\u3055\u308c\u308bVeeva R&D and Quality Summit<\/a><\/strong>\u3067\u3082\u8a73\u3057\u304f\u53d6\u308a\u4e0a\u3052\u3089\u308c\u307e\u3059\u3002\u3053\u306e\u30d0\u30fc\u30c1\u30e3\u30eb\u30a4\u30d9\u30f3\u30c8\u306f\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u696d\u754c\u95a2\u4fc2\u8005\u9650\u5b9a\u306e\u30a4\u30d9\u30f3\u30c8\u3067\u3059\u3002\u53c2\u52a0\u767b\u9332\u304a\u3088\u3073\u6700\u65b0\u60c5\u5831\u306b\u3064\u3044\u3066\u306fveeva.com\/R&DSummit<\/a><\/strong>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002\u307e\u305f\u3001veeva.com\/EUSummit<\/a><\/strong>\u306b\u3066Veeva R&D and Quality Summit, Europe\u3067\u516c\u958b\u3055\u308c\u305f\u30bb\u30c3\u30b7\u30e7\u30f3\u3092\u30aa\u30f3\u30c7\u30de\u30f3\u30c9\u3067\u3054\u8996\u8074\u3044\u305f\u3060\u3051\u307e\u3059\u3002<\/p>\n <\/p>\n \u3010<\/strong>Veeva Systems<\/strong>\u793e\u306b\u3064\u3044\u3066\u3011<\/strong> \u3010Forward-looking Statements\u3011 Bayer AG\u793eJoerg Moeller\u6c0f\uff1aVeeva\u306e\u30af\u30e9\u30a6\u30c9\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u3067\u3001\u5f53\u793e\u306f\u81e8\u5e8a\u8a66\u9a13\u306e\u5b9f\u65bd\u3092\u30b9\u30ea\u30e0\u5316\u3067\u304d\u308b\u3067\u3057\u3087\u3046\u3002<\/p>\n","protected":false},"author":131,"featured_media":43980,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[322,341],"tags":[],"class_list":["post-43973","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","category-case-study"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/43973"}],"collection":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/comments?post=43973"}],"version-history":[{"count":4,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/43973\/revisions"}],"predecessor-version":[{"id":44066,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/43973\/revisions\/44066"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/media\/43980"}],"wp:attachment":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/media?parent=43973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/categories?post=43973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/tags?post=43973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nVeeva Systems\u3010NYSE:VEEV\u3011(\u672c\u793e : \u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e : \u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79 : \u5ca1\u6751 \u5d07\u3001\u4ee5\u4e0b Veeva) \u306f\u3001Bayer AG\u793e\uff08ETR:BAYN\uff09\u304c\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u306b\u304a\u3051\u308b\u8a66\u9a13\u306e\u30b9\u30bf\u30fc\u30c8\u30a2\u30c3\u30d7\u3092\u52a0\u901f\u3057\u3001\u81e8\u5e8a\u8a66\u9a13\u5168\u4f53\u306e\u53ef\u8996\u6027\u3092\u5411\u4e0a\u3055\u305b\u308b\u305f\u3081\u3001Veeva Vault Study Startup<\/a><\/strong>\u3068Veeva Vault eTMF<\/a><\/strong>\u3092\u30b0\u30ed\u30fc\u30d0\u30eb\u3067\u63a1\u7528\u3057\u305f\u3068\u767a\u8868\u3057\u307e\u3057\u305f\u3002(\u672c\u30ea\u30ea\u30fc\u30b9\u306f\u3001Veeva\u7c73\u56fd\u672c\u793e\u304c\u767a\u8868\u3057\u305f\u5831\u9053\u8cc7\u6599\u306e\u6284\u8a33\u3067\u3059\u3002\u539f\u6587\u306f\u3053\u3061\u3089<\/a><\/strong>\u304b\u3089\u304a\u8aad\u307f\u3044\u305f\u3060\u3051\u307e\u3059\u3002)<\/p>\n
\nVeeva Systems\u793e\u306f\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u5411\u3051\u306b\u30af\u30e9\u30a6\u30c9\u30d9\u30fc\u30b9\u306e\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u3092\u63d0\u4f9b\u3059\u308b\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u3067\u3059\u3002\u4e16\u754c\u6700\u5927\u898f\u6a21\u306e\u88fd\u85ac\u4f1a\u793e\u304b\u3089\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5206\u91ce\u306e\u65b0\u8208\u4f01\u696d\u307e\u3067\u3001875\u793e\u3092\u8d85\u3048\u308b\u9867\u5ba2\u306b\u6280\u8853\u9769\u65b0\u3078\u306e\u53d6\u308a\u7d44\u307f\u3084\u5353\u8d8a\u3057\u305f\u88fd\u54c1\u529b\u306b\u3088\u3063\u3066\u3001\u304a\u5ba2\u69d8\u306e\u6210\u529f\u306b\u30b3\u30df\u30c3\u30c8\u3059\u308b\u69d8\u3005\u306a\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002Veeva\u306f\u3001\u30b5\u30f3\u30d5\u30e9\u30f3\u30b7\u30b9\u30b3\u306e\u30d9\u30a4\u30a8\u30ea\u30a2\u306b\u672c\u793e\u3092\u7f6e\u304d\u3001\u30e8\u30fc\u30ed\u30c3\u30d1\u3001\u30a2\u30b8\u30a2\u3001\u30e9\u30c6\u30f3\u30a2\u30e1\u30ea\u30ab\u306b\u62e0\u70b9\u3092\u5c55\u958b\u3057\u3066\u3044\u307e\u3059\u3002
\n\u8a73\u3057\u304f\u306f\u3001https:\/\/veeva.com\/jp\/<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n
\nThis release contains forward-looking statements, including the market demand for and acceptance of Veeva\u2019s products and services, the results from use of Veeva\u2019s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended April 30, 2020. This is available on the company\u2019s website at veeva.com under the Investors section and on the SEC\u2019s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.<\/p>\n","protected":false},"excerpt":{"rendered":"